Abstract
Vaccines have been considered in treating many CNS degenerative disorders, including Alzheimers disease (AD), Parkinsons disease (PD), Huntingtons disease (HD), epilepsy, multiple sclerosis (MS), spinal cord injury (SCI), and stroke. DNA vaccines have emerged as novel therapeutic agents because of the simplicity of their generation and application. Myelin components such as NOGO, MAG and OMGP are known to trigger demyelinating autoimmunity and to prevent axonal regeneration. For these reasons DNA vaccines encoding NOGO, MAG and OMGP, and fragments thereof, make them suitable vehicles for treatment of SCIs and MS. We need to obtain a deeper understanding of the immunologic mechanisms underlying the neuroprotective immunity to optimize the design of DNA vaccines for their use in clinical setting. In this review, we discuss recent findings suggesting that DNA vaccines hold a promising future for the treatment of axonal degeneration and demyelination.
Keywords: DNA vaccine, NOGO, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMGP), regeneration, spinal cord injury, multiple sclerosis, autoimmunity
Current Pharmaceutical Design
Title: DNA Vaccine and the CNS Axonal Regeneration
Volume: 13 Issue: 24
Author(s): Du-yu Nie, Gang Xu, Sohail Ahmed and Zhi-cheng Xiao
Affiliation:
Keywords: DNA vaccine, NOGO, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMGP), regeneration, spinal cord injury, multiple sclerosis, autoimmunity
Abstract: Vaccines have been considered in treating many CNS degenerative disorders, including Alzheimers disease (AD), Parkinsons disease (PD), Huntingtons disease (HD), epilepsy, multiple sclerosis (MS), spinal cord injury (SCI), and stroke. DNA vaccines have emerged as novel therapeutic agents because of the simplicity of their generation and application. Myelin components such as NOGO, MAG and OMGP are known to trigger demyelinating autoimmunity and to prevent axonal regeneration. For these reasons DNA vaccines encoding NOGO, MAG and OMGP, and fragments thereof, make them suitable vehicles for treatment of SCIs and MS. We need to obtain a deeper understanding of the immunologic mechanisms underlying the neuroprotective immunity to optimize the design of DNA vaccines for their use in clinical setting. In this review, we discuss recent findings suggesting that DNA vaccines hold a promising future for the treatment of axonal degeneration and demyelination.
Export Options
About this article
Cite this article as:
Du-yu Nie , Gang Xu , Sohail Ahmed and Zhi-cheng Xiao , DNA Vaccine and the CNS Axonal Regeneration, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368567
DOI https://dx.doi.org/10.2174/138161207781368567 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology The Role of Topiramate and Other Anticonvulsants in the Treatment of Alcohol Dependence: A Clinical Review
CNS & Neurological Disorders - Drug Targets The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs
Current Pharmaceutical Design The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism The Role of Spiritual Health Experience with Intensity and Duration of Labor Pain While Childbearing and Postpartum
Current Women`s Health Reviews Isoniazid Induced Convulsions at Therapeutic Dose in an Alcoholic and Smoker Patient
Current Drug Safety Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review
Current Alzheimer Research Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Editorial
Current Pediatric Reviews Efficient High-throughput Techniques for the Analysis of Disease- Resistant Plant Varieties and Detection of Food Adulteration
Current Protein & Peptide Science Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) The New Antiepileptic Drugs Pharmacological and Clinical Aspects
Current Pharmaceutical Design Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain
Current Pharmaceutical Design Citrus Peel Extract Attenuates Acute Cyanide Poisoning-Induced Seizures and Oxidative Stress in Rats
CNS & Neurological Disorders - Drug Targets Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Anticonvulsant and Antitubercular Activities of 6-Phenyl/Biphenyl-4-yl-2- [2-(pyridin-2-ylamino)-ethyl]- and 6-(Biphenyl-4yl)-2-(2N-subtituted amin- 1-yl)-ethyl derivatives of 4,5-dihydropyridazin-3(2H)-one
Letters in Drug Design & Discovery Insights into Anti-Trypanosomal Agents Based on Synthetic Glycoconjugates
Current Topics in Medicinal Chemistry